Gentherm Medical Receives FDA Clearance for ThermAffyx™ Patient Safety System

Rhea-AI Summary

Gentherm (THRM) announced FDA 510(k) clearance for its patented ThermAffyx™ Patient Safety System, a Class II medical device that integrates active underbody warming, securement and pressure reduction for robotic-assisted surgery, a market the company notes includes more than 3 million procedures annually worldwide.

ThermAffyx replaces separate warming and securement solutions with a single system designed to fit into existing robotic surgical workflows, particularly procedures using the Trendelenburg position where only 17%–21% of body surface may be accessible to forced-air warming and over one-quarter of patients can be hypothermic in recovery. The device incorporates a radiolucent heating element powered by Gentherm’s proprietary Carbotex® carbon-fiber technology. Product trials at healthcare facilities are scheduled to begin in August, with revenue generation expected by Gentherm to commence in Q3 2026. According to the company, this clearance significantly expands its patient temperature management portfolio.

Positive

• FDA 510(k) clearance for ThermAffyx Class II patient safety system
• Targets 3+ million robotic-assisted surgeries performed annually worldwide
• Product trials start August with revenue expected Q3 2026
• Expands Gentherm’s patient temperature management portfolio
• Uses proprietary Carbotex carbon-fiber heating technology

Negative

• None.

News Market Reaction – THRM

+3.01%

+3.01% Session close to close

In the Jul 21 session, THRM gained 3.01%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

THRM’s short positioning was classified as low in the platform data. That context leaves the FDA cle...

Analysis

THRM’s short positioning was classified as low in the platform data. That context leaves the FDA clearance to be assessed through August trial starts and Q3 2026 revenue execution, with commercialization timing requiring monitoring.

Key Figures

FDA clearance: FDA 510(k) clearance Device classification: Class II Addressable procedures: more than 3 million procedures annually +4 more

7 metrics

FDA clearance FDA 510(k) clearance ThermAffyx Patient Safety System

Device classification Class II Medical device classification

Addressable procedures more than 3 million procedures annually Robotic-assisted surgical procedures worldwide

Trial start August Product trials at healthcare facilities

Revenue timing Q3 2026 Expected revenue generation commencement

Available body surface area 17% to 21% Available for forced-air warming during certain procedures

Postoperative hypothermia more than one-quarter Robotic surgery patients hypothermic in recovery

Historical Context

5 past events · Latest: Jul 07 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 07	Earnings date notice	Neutral	+0.0%	Announced second-quarter results release date and conference call timing
May 26	Supplier award	Positive	+3.1%	Received General Motors Supplier of the Year recognition for the fourth time
May 20	Investor conferences	Neutral	+2.1%	Announced participation in several second-quarter investor conferences
May 14	Product showcase	Neutral	+2.3%	Planned demonstrations of wellness technologies at NeoCon 2026
Apr 23	Quarterly earnings	Positive	+3.0%	Reported record first-quarter product revenue and maintained full-year guidance

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The five listed recent events were followed by four positive reactions and one zero reaction.

Key Terms

510(k), class ii medical device, trendelenburg position, radiolucent

4 terms

510(k) regulatory

"received FDA 510(k) clearance for its patented ThermAffyx"

A 510(k) is a U.S. regulatory submission that a medical device maker uses to show a new device is as safe and effective as an already-approved device, allowing the regulator to clear it for sale rather than requiring the longer, more stringent approval process. For investors, a cleared 510(k) usually means lower regulatory risk and a faster path to market, which can speed revenue generation and reduce uncertainty—similar to proving a new appliance works like a trusted existing model.

class ii medical device regulatory

"This Class II medical device combines active patient warming"

A class II medical device is a product that poses moderate risk to patients and therefore must meet specific regulatory rules for safety and performance beyond basic checks but not the most stringent requirements used for highest-risk devices. For investors, this classification signals predictable but nontrivial development costs and approval steps—usually longer and more expensive than the lowest-risk products but clearer and faster than the highest-risk ones—affecting time to market, potential liabilities, and revenue forecasts.

trendelenburg position medical

"surgeries that require the patient to be tilted in Trendelenburg position"

A position in which a person lies on their back with the head lower than the feet, typically achieved by tilting a bed or table so the pelvis is higher than the head. It is used in medical settings to change blood flow and organ position—think of tilting a board so fluid moves toward one end—and matters to investors because it affects design and use of hospital beds, surgical tables, emergency care protocols, and related medical-device and facility costs.

radiolucent technical

"The radiolucent heating element is powered by Gentherm's"

Radiolucent describes a material or substance that lets X-rays or similar imaging radiation pass through it more easily, so it appears darker or less visible on radiographic images. For investors, the property matters because it affects how medical devices, implants, and diagnostic tools perform in scans—like a window versus a wall in an X-ray—impacting product design, clinical utility, regulatory review, and market acceptance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

The company’s new patented integrated warming and securement device seamlessly addresses unique challenges in robotic surgery

NOVI, Mich., July 20, 2026 (GLOBE NEWSWIRE) -- Gentherm, a global market leader of innovative thermal management and pneumatic comfort technologies, announced today it received FDA 510(k) clearance for its patented ThermAffyx™ Patient Safety System. This Class II medical device combines active patient warming, securement and pressure reduction in a single platform designed for the more than 3 million robotic-assisted surgical procedures performed annually worldwide. Product trials at healthcare facilities are scheduled to begin in August, with revenue generation expected to commence in Q3 2026.

Historically, surgical teams have pieced together separate solutions to address warming and securement issues. ThermAffyx simplifies that process by combining two critical patient safety functions into a single system that fits naturally into existing surgical workflows.

Traditional underbody securement pads help prevent patient movement but do not provide active warming. This is especially problematic in robotic procedures and surgeries that require the patient to be tilted in Trendelenburg position. Studies have found that only 17% to 21% of a patient's body surface area may be available for forced-air warming during these procedures, and more than one-quarter of robotic surgery patients are hypothermic in recovery, despite warming interventions.

The ThermAffyx Patient Safety System was developed to address this gap by integrating active underbody warming directly into an anti-slip securement pad. The radiolucent heating element is powered by Gentherm's proprietary Carbotex® carbon-fiber heating technology. This is more than a new warming device. It's a purpose-built patient safety platform designed around the realities of modern robotic surgery. 

The FDA clearance follows Gentherm's 510(k) submission announced earlier this year and represents a significant expansion of the company's patient temperature management portfolio.

About Gentherm
Gentherm (NASDAQ: THRM) is a global market leader of innovative thermal management and pneumatic comfort technologies. Automotive products include Climate Control Seats (CCS®), Climate Control Interiors (CCI™), Lumbar and Massage Comfort Solutions, and Valve Systems. Medical products include patient temperature management systems. The Company is also developing a number of new technologies and products that will help enable improvements to existing products and to create new product applications for existing and new markets. Gentherm has more than 14,000 employees in facilities across 13 countries. In 2025, the company recorded annual sales of approximately $1.5 billion and secured $2.2 billion in automotive new business awards. For more information, go to www.gentherm.com. 

Investor Contact 
Gregory Blanchette
investors@gentherm.com
248.308.1702

Media Contacts
Haley Baur
media@gentherm.com
248.289.9711

FAQ

What is Gentherm's ThermAffyx Patient Safety System (THRM) and what surgeries is it designed for?

ThermAffyx is a Class II patient safety system combining active warming, securement and pressure reduction for robotic-assisted surgery. According to Gentherm, it is purpose-built for modern robotic procedures, including those using the Trendelenburg position where traditional forced-air warming is limited.

What does FDA 510(k) clearance of ThermAffyx mean for Gentherm (THRM)?

FDA 510(k) clearance allows Gentherm to market ThermAffyx as a cleared Class II medical device in the U.S. According to Gentherm, this regulatory milestone significantly expands its patient temperature management portfolio and supports entry into the growing robotic-assisted surgery segment.

When will Gentherm (THRM) start ThermAffyx product trials and expect revenue?

Gentherm plans to begin ThermAffyx product trials at healthcare facilities in August. According to Gentherm, revenue generation from the ThermAffyx Patient Safety System is expected to commence in the third quarter of 2026, following these initial clinical evaluations and customer adoption efforts.

How does ThermAffyx improve patient warming in robotic surgery for Gentherm (THRM)?

ThermAffyx integrates active underbody warming into an anti-slip securement pad to address limited warming surface area. According to Gentherm, studies show only 17%–21% body surface is available for forced-air warming and over one-quarter of robotic patients are hypothermic postoperatively.

What proprietary technology powers Gentherm's ThermAffyx Patient Safety System (THRM)?

ThermAffyx uses a radiolucent heating element powered by Gentherm’s proprietary Carbotex carbon-fiber heating technology. According to Gentherm, this integrated heating is combined with securement and pressure reduction in a single platform that fits existing robotic surgery workflows and imaging requirements.

How large is the target market for Gentherm's ThermAffyx system (THRM)?

ThermAffyx is designed for the global market of robotic-assisted surgical procedures. According to Gentherm, there are more than 3 million such procedures performed annually worldwide, providing a sizable potential customer base for the new patient safety and warming platform.